Akebia Therapeutics (AKBA) said Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Xoanacyl for treating elevated serum phosphorus and iron deficiency in adults with chronic kidney disease.
The company said Averoa, a biopharmaceutical company specializing in renal treatments, licensed the rights from Akebia to develop and market ferric citrate in the European Economic Area and certain countries in Europe and the Middle East.
The European Commission is expected to reach a final decision on Xoanacyl's approval within about two months, the biopharmaceutical company said.
Shares of Akebia were down more than 3% in recent Thursday trading.
Price: 1.87, Change: -0.06, Percent Change: -3.11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.